Finally, as noted above [160,161] and in sharp contrast to other tumor types [199], in AML cells, PI3K/Akt inhibitors may disrupt, rather than activate, the complementary Ras/Raf/MEK/ERK survival signaling pathway, activated in >80% of AML samples [200], through an unknown mechanism. The gene discussed is AKT1; the disease is acute myeloid leukemia.